---
schema_version: "secwatch.filing_event.v1"
accession: "0001790340-24-000054"
form_type: "8-K"
ticker: "IMRX"
cik: "0001790340"
company_name: "Immuneering Corp"
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T19:34:17.893500+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Immuneering reports Q1 net loss $14.3M; Phase 2a data for IMM-1-104 expected in 2024

## Summary
- Net loss $14.3M ($0.49/share) vs $13.6M ($0.51) Q1 2023; R&D expense $11.2M up from $10.2M.
- Phase 1 data for IMM-1-104 shows well-tolerated safety; target lesion regression in >50% of patients at 320mg.
- First patient dosed in Phase 2a of IMM-1-104; initial data from multiple arms expected in 2024.
- First patient dosed in Phase 1/2a of IMM-6-415 (RAF/RAS mutations); initial PK/PD/safety data expected 2024.
- FDA Fast Track designation for IMM-1-104 in pancreatic cancer; cash $71.3M expected to fund operations into H2 2025.

## SEC filing metadata
- accession: 0001790340-24-000054
- form_type: 8-K
- ticker: IMRX
- cik: 0001790340
- company_name: Immuneering Corp
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1790340/000179034024000054/0001790340-24-000054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1790340/000179034024000054/imrx-20240507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001790340-24-000054
- JSON: https://secwatch.observer/filing/0001790340-24-000054.json
- Plain text: https://secwatch.observer/filing/0001790340-24-000054.txt

## Key facts
- Earnings Releases
  Immuneering Corp reported the first quarter ended March 31, 2024 results: net income Net loss attributable to common stockholders was $14.3 million, or $0.49 per share, EPS $0.49 per share.
  - Period: the first quarter ended March 31, 2024
  - Net income: Net loss attributable to common stockholders was $14.3 million, or $0.49 per share
  - EPS: $0.49 per share
  - Result: reported results
  source text: Immuneering Corporation (the “Company”) announced its financial results for the quarter ended March 31, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1790340/000179034024000054/0001790340-24-000054-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.